Much clinical evidence shows the presence of secondary mutations that functionally restore BRCA1 and BRCA2 proteins in platinum-resistant ovarian tumors [46,47,48], and also in BRCA1/2-mutated ovarian carcinomas that are resistant to olaparib [7,49]. The gene discussed is BRCA1; the disease is ovarian neoplasm.